复星抗癌新药首次公布临床数据,具备“同类最优”开发潜力

中金在线
03 Jun

5月30日至6月3日,2025年美国临床肿瘤学会(ASCO)年会在芝加哥举行。大会期间,复星国际(00656.HK)创新生物药平台——复宏汉霖连续发布多项围绕癌症治疗的最新突破,受到高度关注。本次ASCO年会上,复宏汉霖首次公布了HLX43(PD-L1 ADC)治疗晚期/转移性实体瘤患者的I期临床试验数据。凭借精准的分子设计和多重创新机制,HLX43在晚期/转移性实体瘤患者中显示出优异的抗肿瘤活性...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10